UNC to Receive $26.9M from DARPA to Develop Psychiatric Medicines
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
Scientific Research - Page 17
Solved: The Crystal Structure of N-Methyl-N-Propyltryptamine (MPT)
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Psychedelics May Relieve Chronic Pain Via Changes in Brain Neuroplasticity
Using psychedelics to treat chronic pain is understudied yet full of potential.
MDMA for PTSD Showing Promising Outcomes for Patients in MAPS Phase 3 Trials
“In the pharmaceutical drug development community, this is what you dream about.”
Noribogaine is More Effective Than Fluoxetine in Reducing Depressive Symptoms in Rat Model
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
CaaMTech Partners with the National Institutes of Health to Study Synthetic Tryptamines
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
Antidepressant-Like Effect with A Single Dose of Ibogaine and Noribogaine in Rats
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Scientists Solve the Crystal Structure of the Freebase of 5-MeO-DALT
Understanding the structure of this synthetic analog of 5-MeO-DMT may help explain the effects of naturally occurring chemical cocktails.
Two New Crystalline Forms of Norpsilocin
New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.
Brain Morphology May Help Explain Differing Psilocybin Experiences
Understanding brain morphology differences may prove essential for creating effective psychedelic drug formulations.